Post-licensure surveillance of trivalent live-attenuated influenza vaccine in children aged 2-18 years, vaccine adverse event reporting system, United States, July 2005-June 2012

Journal of the Pediatric Infectious Diseases Society

Volumn 4, Issue 3, 2015, Pages 205-213

  Haber, Penina ^a   Moro, Pedro L ^a   Cano, Maria ^a   Vellozzi, Claudia ^a   Lewis, Paige ^a   Woo, Emily Jane ^b   Broder, Karen ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Live attenuated influenza; Postmarketing surveillance; Vaccine; Vaccine safety

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE; LIVE VACCINE;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; DATA MINING; DRUG SURVEILLANCE PROGRAM; FEBRILE CONVULSION; FEMALE; GUILLAIN BARRE SYNDROME; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LICENCE; MALE; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; MEDICAL RECORD; MEDICATION ERROR; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEASONAL VARIATION; SEIZURE; UNITED STATES; WHEEZING; BACTERIAL INFECTIONS; CHEMICALLY INDUCED; COMPLICATION; GUILLAIN-BARRE SYNDROME; HYPERSENSITIVITY; INFLUENZA, HUMAN; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; SEIZURES;

ADOLESCENT; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; HYPERSENSITIVITY; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; SEIZURES; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 85006201237     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piu034     Document Type: Article

References (37)

1. MedImmune. FluMist [package insert]. Gaithersburg, MD: MedImmune; 2012.
2. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2004. MMWR 2004; 53:3-4.
3. Harper SA, Fukuda K, Uyeki TM, et al. Using live attenuated influenza vaccine for prevention and control of influenza. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003; 52:1-8.
4. Food and Drug Administration. FDA approves nasal influenza vaccine for use in younger children. Rockville, MD: Food and Drug Administration; 2007. Available at http://www.fda.gov/bbs/topics/news/2007/new01705.html. Accessed 12 February 2013.
5. Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008; 26 (Suppl 4):D10-6.
6. Vesikari T, Karvonen T, Smith HM, et al. Safety and tolerability of cold-adapted influenza vaccine trivalent, in infants younger than 6 month of age. Pediatrics 2008; 121:e568-73.
7. Centers for Disease Control and Prevention. Notice to readers: expansion of use of live attenuated influenza vaccine (FluMist) to children aged 2-4 years and other FluMist changes for 2007-08 influenza season. MMWR 2007; 56:1217-9.
8. Fiore AE, Uyeki TM, Broder K, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1-62.
9. Food and Drug Administration. FluMist Quadrivalent (Influenza Vaccine Live, Intranasal). http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM294307.pdf. Accessed 2 July 2012.
10. Toback SL, Levin MJ, Block SL, et al. Quadravalent Ann Arbor strain live-attenuated influenza vaccine. Expert Rev Vaccines 2012; 11:1293-303.
11. Prevention of control of influenzawith vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza seasons. MMWR 2012; 61: 613-18.
12. Grohskopf LA, Shay DK, Shimabukuro TT, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), United States. MMWR 2013; 62(RR07):1-4.
13. Belshe RB, Mendelman PM, Treanor J. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998; 338:1405-12.
14. Izurieta S, Hector, Penina Haber, et al. Adverse events reported following live cold-adapted intranasal influenza vaccine. JAMA 2005; 294:2720-5.
15. Zanardi LR, Haber P, Mootrey GT, et al. Intussusception among recipients of rotavirus vaccine: reports to the Vaccine Adverse Event Reporting System. Pediatrics 2001; 107:E97.
16. Varricchio F, Iskander J, DeStefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23:287-94.
17. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) United States, 1991-2001. MMWR Surveill Summ 2003; 52:1-24.
18. Medical Dictionary for Regulatory Activities. Available at: http://www.meddramsso.com. Accessed 13 February 2013.
19. Food and Drug Administration. 21 CFR Part 600.80. Postmarketing reporting of adverse experiences. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=600.80. Accessed 12 February 2013.
20. Vellozzi C, Broder KR, Haber P, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United State, October 1, 2009-January 31, 2010. Vaccine 2010; 28:7248-55.
21. IOM (Institute of Medicine). Adverse Effects of Vaccines: Evidence and Causality. Washington DC: The National Academies Press; 2011.
22. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29:599-612.
23. Ruggeberg JU, Gold MS, Bayes JM, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25:5675-84.
24. DuMouchelW, Pregibon D. Empirical Bayes screening for multiitem associations. In: Proceeding of the Conference on Knowledge Discovery and Data; August 26-29, 2001; San Diego, CA: ACM Press:67-76.
25. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higherthan-expected combinations of drugs and events in the US FDA's Spontaneous Reports database. Drug Safety 2002; 25:381-92.
26. Tennis P, Toback SL, Andrews EB, et al. Postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. Vaccine 2011; 29:4947-52.
27. Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age. Vaccine 2012; 30:2989-98.
28. Toback SL, Ambrose CS, Eaton A, et al. postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age. Vaccine 2013; 31: 1812-8.
29. Moro PL, Broder K, Zheteyeva Y, et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol 2011; 204:146.e1-7.
30. Baxter R, Bakshi N, Fireman B, et al. Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis 2013; 57:197-204.
31. Kawai AT, Li L, Kulldorff M, et al. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. Pharmacoepidemiol Drug Saf 2014; Feb 4. doi:10.1002/pds.3575.
32. Sejvar JJ, Baughman AL, Wise M, et al. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36:123-33.
33. McNeil MM, Arana J, Stewart B, et al. A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination-possible stimulated reporting? Vaccine 2012; 30:2421-6.
34. Vasu N, Ghaffari G, Craig ET, et al. Adverse events associated with intranasal influenza vaccine in United States. Ther Adv Respir Dis 2008; 2:193-8.
35. Kelso JM, Greenhawt MJ, Li JT. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol 2012; 130:25-43.
36. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-96.
37. IOM (Institute of Medicine) 2007. Preventing Medication Errors: Quality Chasm Series. Committee on Identifying and Preventing Medication Errors. National Academy of Sciences Press.